SEC Form 4 · accession 0001873905-26-000002
Candel Therapeutics, Inc. · CADL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul Peter Tak
Officer — Chief Executive Officer · Director
Period of report
Sep 10, 2026
Accepted (ET)
Sep 11, 2026 · 6:12 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001841387
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 10, 2026 | M | 125,000 | $1.55 | A | 393,566 | D | |
| Common StockF2 | Sep 10, 2026 | S | 220,866 | $11.4997 | D | 172,700 | D | |
| Common StockF3 | Sep 11, 2026 | S | 59,379 | $10.4564 | D | 113,321 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $1.55 | Sep 10, 2026 | M | 125,000 | D | — | Oct 10, 2030 | Common Stock | 125,000 | 1,638,968 | D |
Explanation of responses
- F1This transaction reported on this Form 4 was effected pursuant to a 10b5-1 plan adopted on 3/13/2026 and modified on 6/11/2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.20 to $12.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 herein.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.86 to $11.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 herein.
- F425% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on September 14, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.